Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 72 points (0.5%) at 14,749 as of Thursday, April 25, 2013, 12:50 PM ET. The NYSE advances/declines ratio sits at 2,049 issues advancing vs. 833 declining with 158 unchanged. The Health Services industry currently sits up 0.5% versus the S&P 500, which is up 0.7%. A company within the industry that fell today was Aetna ( AET), up 0.90. Top gainers within the industry include Icon ( ICLR), up 9.4%, Zimmer Holdings ( ZMH), up 1.6%, Stryker Corporation ( SYK), up 1.5%, Becton Dickinson ( BDX), up 1.4% and Edwards Life ( EW), up 1.4%. TheStreet Ratings group would like to highlight 3 stocks pushing the industry lower today: 3. Ironwood Pharmaceuticals ( IRWD) is one of the companies pushing the Health Services industry lower today. As of noon trading, Ironwood Pharmaceuticals is down $0.89 (-5.5%) to $15.41 on heavy volume Thus far, 1.0 million shares of Ironwood Pharmaceuticals exchanged hands as compared to its average daily volume of 792,600 shares. The stock has ranged in price between $15.25-$16.32 after having opened the day at $16.28 as compared to the previous trading day's close of $16.30. Ironwood Pharmaceuticals, Inc., an entrepreneurial pharmaceutical company, discovers, develops, and commercializes human therapeutic products. Ironwood Pharmaceuticals has a market cap of $1.4 billion and is part of the health care sector. Shares are up 51.4% year to date as of the close of trading on Wednesday. TheStreet Ratings rates Ironwood Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income and weak operating cash flow. Get the full Ironwood Pharmaceuticals Ratings Report now. Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.